NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.

Br J Cancer · 2024 · PMC10844282 · PMID 38135713

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

When stratifying PFS and OS by HRD status, we observed a trend towards improved PFS and OS that did not reach statistical significance, although the analysis was underpowered for these endpoints.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.